Unecritinib

安奈克替尼

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameUnecritinib
Drug Alias Name富马酸安奈克替尼Unecritinib fumarate安柏尼TQ-B3101TTQ-B3101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitorsHepatocyte growth factor receptor inhibitors
TargetsProto-oncogene tyrosine-protein kinase ROSAnaplastic lymphoma kinaseHepatocyte growth factor receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[6] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/04/24
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdSoutheast University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesSoutheast UniversityNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsLymphoma, Large-Cell, AnaplasticNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A